Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.58 |
| ▸ | PDE4A | P27815 | 3/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2473169 | 0.96 | ADORA2A (0.53) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3170806 | 0.94 | ADORA2A (0.52) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3170224 | 0.94 | ADORA2A (0.52) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3188565 | 0.94 | ADORA2A (0.52) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| Water SCHEMBL19583233 | 0.94 | ADORA2A (0.52) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15026860 | 0.94 | ADORA2A (0.52) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3180528 | 0.91 | ADORA2A (0.59) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2524674 | 0.86 | ADORA2A (0.45) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2524110 | 0.86 | ADORA2A (0.45) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2472434 | 0.85 | ADORA2A (0.44) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | claimed |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | SHANTON PHARMA CO., LTD (CN) | 2019-06-18 | — | — | US | claimed |
| EP-3251675-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Co., Ltd. (CN) | 2017-12-06 | — | — | EP | claimed |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Pte. Ltd. (SG) | 2017-11-16 | — | — | US | claimed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | claimed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | claimed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | claimed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | claimed |
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | disclosed |
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | disclosed |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | SHANTON PHARMA CO., LTD (CN) | 2019-06-18 | — | — | US | disclosed |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | SHANTON PHARMA CO., LTD (CN) | 2019-06-18 | — | — | US | disclosed |
| EP-3251675-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Co., Ltd. (CN) | 2017-12-06 | — | — | EP | disclosed |
| EP-3251675-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Co., Ltd. (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| EP-1781657-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2005077950-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| EP-1030666-A4 | NOVEL USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY | SMITHKLINE BEECHAM (US) | 2002-10-16 | — | — | EP | disclosed |
| EP-1030666-A1 | NOVEL USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY | Smithkline Beecham (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999020280-A1 | NOVEL USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135456-A1 | Medicaments with hm74a receptor activity | HCAR1, GPR84, HCAR3 | ADORA2A 12/4885PDE4A 679/4885PDE4B 1199/4885 |
| US-20150080418-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | ADORA2A 8/4885PDE4A 408/4885PDE4B 592/4885 |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | NLRP3, REN, SLC5A1 | ADORA2A 2329/4885PDE4A 3392/4885PDE4B 3496/4885 |
| US-20130150383-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | ADORA2A 8/4885PDE4A 408/4885PDE4B 592/4885 |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | REN, NLRP3, SLC5A1 | ADORA2A 2737/4885PDE4A 3590/4885PDE4B 3708/4885 |
| US-20100010021-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | ADORA2A 8/4885PDE4A 408/4885PDE4B 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.